DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
DarioHealth Corp.NASDAQ: DRIO
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses turns positive
Q1 FY2026 operating expenses was $10.51M, compared with -$5.53M a year earlier. Trailing-twelve-month operating expenses was $65.36M. Over 3 fiscal years it compounded at -9.5% a year.
Context
- Operating expenses amounted to 220.6% of revenue in FY2025, down 42.0 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating expenses holds near $10.51M or moves back toward the trailing-twelve-month quarterly average of $16.34M.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 49.32M USD
- Year-over-year change
- -30.5%
- 4-year CAGR
- -12.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.32M | -30.5% |
| FY2024 | 2024-12-31 | 71.01M | +14.2% |
| FY2023 | 2023-12-31 | 62.17M | -6.5% |
| FY2022 | 2022-12-31 | 66.47M | -21.4% |
| FY2021 | 2021-12-31 | 84.56M | — |
Operating Expenses vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 operating expenses of $65.36M is the 10th highest of the 11 companies compared; the peer median is $226.03M.
- Its year-over-year change of +312.8% is the highest of 11, against a peer median of +8.8%.
- Operating expenses amounts to 308.4% of revenue for DRIO, versus a peer median of 94.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $963.5M | +36.4% | +1.5% | 116.2% | |
| LTM Mar 2026 | $602.92M | -6.4% | +21.0% | 73.0% | |
| LTM Mar 2026 | $404.3M | +24.4% | +5.2% | 56.5% | |
| LTM Mar 2026 | $256.57M | -7.5% | -1.0% | 292.1% | |
| LTM Mar 2026 | $229.94M | +24.0% | +5.6% | 71.8% | |
| LTM Mar 2026 | $222.12M | -73.8% | +19.5% | 138.8% | |
| LTM Mar 2026 | $212.38M | +50.5% | +37.4% | 428.3% | |
| LTM Mar 2026 | $159.23M | -12.2% | +63.8% | 16.8% | |
| LTM Mar 2026 | $104.36M | +58.2% | +29.3% | 5683.9% | |
| LTM Mar 2026 | $65.36M | +312.8% | -9.5% | 308.4% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $2M | -48.5% | -5.4% | 20.5% |
| Peer median (excluding DRIO) | $226.03M | +8.8% | +12.6% | 94.6% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.